High Intensity Focused Ultrasound (HIFU) Market is estimated to be valued at USD 129.8 Mn in 2025 and is expected to reach USD 210.6 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 7.16% from 2025 to 2032.
The High Intensity Focused Ultrasound (HIFU) market is propelled by the growing need for non-invasive and accurate therapeutic solutions for treating cancer, such as prostate, uterine fibroids, and liver tumors. Increasing patient interest in minimally invasive treatments with shorter recovery times and lesser side effects is driving adoption. Advances in MRI-guided system and ultrasound-guided HIFU systems have improved treatment efficacy and broadened clinical indications. The market is also supported by increasing awareness among patients and healthcare providers, as well as increasing healthcare infrastructure in developing economies.
|
Current Events |
Description and its impact |
|
EDAP TMS Installs Focal One HIFU System in Canadian Hospitals |
|
|
Sonablate Corp and Mayo Clinic Collaborate on AI-Directed HIFU Study |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The High Intensity Focused Ultrasound (HIFU) market exhibits a varied pricing structure influenced by factors such as treatment indication, system sophistication, manufacturer, and service model. The average cost of a HIFU system ranges from $100,000 to over $500,000, depending on the clinical application (e.g., prostate cancer, uterine fibroids, or neurological disorders), imaging integration (MRI or ultrasound-guided), and treatment precision.
In established economies like the U.S., Germany, and Japan, HIFU equipment fetches higher prices because of stricter regulatory requirements, higher-level imaging compatibility, and the need for non-surgical cancer treatments. MRI-guided HIFU machines, for example, are costlier because of the added imaging functionality and typically cost more than $400,000 per machine. Ultrasound-guided HIFU, although less expensive, is still a heavy investment with equipment averaging $150,000 to $250,000.
Procedure prices also differ region by region. Single HIFU procedures in North America and Europe may be priced between $10,000 and $25,000, varying according to the medical condition, type of hospital, and insurance coverage. Lower procedure prices in Asia-Pacific, most notably in China and South Korea, are driving increased uptake through lower-priced treatment packages and state-sponsored programs.
Though the initial cost is high, HIFU is cost-saving in the long run through lower hospitalization, shorter recovery, and fewer complications than invasive surgery. The prices will stabilize as the technology matures and the competition grows, making HIFU available to an increased number of healthcare facilities worldwide.
Current patient and consumer surveys in the High Intensity Focused Ultrasound (HIFU) market show increasing recognition and interest in non-surgical therapeutic technologies, especially for prostate cancer, uterine fibroids, liver tumors, and neurosurgery. The most common reasons mentioned by patients for preferring HIFU over traditional treatments are less recovery time, lesser pain, and no surgical incisions. In a 2024 North American patient satisfaction survey, more than 85% of HIFU-treated patients reported successful outcomes, with convenience ratings being high and minimal post-treatment side effects.
Yet, consumer responses also identify several unserved needs and issues. Patients report many in being unable to access High Intensity Focused Ultrasound (HIFU) for acne scars treatments, mainly based on limited facilities, particularly in rural or underserved areas. Furthermore, insufficient insurance coverage and high copayments are important obstacles to wider use. Some physicians and patients describe differences in treatment outcomes according to tumor type and stage, necessitating further standardization and long-term results data.
Another highly reported gap is insufficient information on HIFU's relative advantages and disadvantages. Patients are said to often feel uneducated about how HIFU weighs against surgery, chemotherapy, or radiation—implying greater educational outreach. Though HIFU is picking up good momentum because of its minimally invasive procedure and high patient satisfaction rates, cost, accessibility, and awareness remain the prime unmet needs to be fulfilled to realize its maximum market potential.
Major companies operating in the global high-intensity focused ultrasound (HIFU) market are focused on inorganic growth strategies such as partnerships, which is expected to drive growth of the global High-Intensity focused ultrasound (HIFU) market over the forecast period.
For instance, in February 2025, Vattikuti Foundation partnered with AIIMS Delhi and InSightec to deploy MR-guided HIFU for treating Parkinson’s disease and essential tremor. The initiative drastically reduced treatment costs and improved access to non-invasive neurological care in India. This collaboration highlights growing global efforts to expand HIFU adoption in emerging markets. It also promotes research into broader neurological applications of the technology.
Increasing prevalence of prostate cancer is expected to drive the market growth over the forecast period as HIFU is used to treat prostate cancer.
For instance, in June 2025, Cleveland Clinic London became the first facility in England to offer robotic focal HIFU for prostate cancer, using a precision-guided robotic arm to ablate only cancerous prostate tissue. The procedure, which preserves healthy tissue and minimizes side effects like incontinence and erectile dysfunction, addresses the growing burden of prostate cancer—which affected over 1.4 million people globally in 2020.
Based on Imaging Technology, the market is segmented into, ultrasound- HIFU therapy and magnetic resonance imaging- HIFU therapy. Out of which, magnetic resonance imaging- HIFU therapy segment is expected to dominate the global high-intensity focused ultrasound (HIFU) market during the forecast period and this is attributed due to increasing R&D activities regarding magnetic resonance imaging- HIFU therapy.
Based on Indication, the market is segmented into oncology (Prostate cancer, Rectal tumors, Liver tumors, Renal tumors, others), skin care (Anti-aging treatment, Skin Laxity and Tightening, Others), neurological disorders, and others (Uterine Fibroids, Benign Prostatic Hyperplasia, etc.). Out of which, oncology segment is expected to dominate the market over the forecast period and this is attributed due to increasing usage of High-Intensity focused ultrasound (HIFU) for the treatment of various cancer/tumor types.
Based on End User, global High-Intensity focused ultrasound (HIFU) market is segmented into hospitals, ambulatory surgical centers, dermatology clinics, and others (Research Institutes, Specialty Centers, etc). Hospitals segment is expected to dominate the market over the forecast period and this is attributed to the usage of HIFU in oncology department in hospitals.
Among imaging technology, Ultrasound- HIFU Therapy held as a dominant segment in 2023 in North America region due to increasing product launches. For instance, in November 2022, TOOsonix A/S, a company in High-Intensity focused ultrasound (HIFU) technology for dermatology, announced that United States Patent and Trademark Office (USPTO) has granted a U.S. patent no. 11/491,351 for its non-invasive treatments of dermatological conditions.
In indication segment, oncology segment is dominant in North America region due to increasing R&D activities. For instance, in November 2022, National Cancer Institute (NCI), a U.S. Government agency for cancer research, initiated a study on Prostate Cancer using radiation therapy. The study is in phase- 2 of clinical trials and is expected to complete by December 2028.
To learn more about this report, Download Free Sample
Among regions, North America is expected to dominate the market over the forecast period, due to the increasing prevalence of vaginal and vulvar cancer in that region. For instance, according to the Centers for Disease Control and Prevention, in November 2025, in U.S., 1,368 women were diagnosed with vaginal cancer and 5,579 women were diagnosed with vulvar cancer in 2019.
Europe is expected to hold second position in global high-intensity focused ultrasound (HIFU) market over the forecast period due to increasing collaborations by key players in that region.
United States leads the market for HIFU due to its advanced healthcare infrastructure, strong research and development, and consequent high use of advanced medical technology. High incidence of prostate cancer and other treatable illnesses, and growing awareness of the use of non-invasive technology, drive demand for HIFU devices in hospitals and specialty clinics.
Germany is a leading market in Europe, supported by its well-established healthcare system and early embracement of advanced medical devices. The country has widespread clinical trials as well as political support for minimal invasive procedures, and it is a hub for the development and use of HIFU technology, especially for oncological applications.
Japan's population aging and strong interest in advanced medical therapy propel strong demand for HIFU procedures. Japan is at the forefront of combining HIFU with MRI guidance and other imaging modalities to enhance treatment precision and effectiveness in uterine fibroid and cancer cases.
China is one of the fastest-growing HIFU markets, fueled by increased spending on healthcare, increasing hospital infrastructure, and increasing awareness of alternative treatments. Government initiatives to promote new medical technology and improve cancer treatment also propel the adoption of HIFU across key urban cities.
South Korea showcases explosive expansion in the HIFU market due to its strong ecosystem of healthcare technologies and superior emphasis on research and innovation. HIFU's popularity for prostate and liver cancer therapies is a testament to the country's leadership in minimally invasive therapy adoption in Asia.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 129.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.16% | 2032 Value Projection: | USD 210.6 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Koninklijke Philips N.V., Sonic Concepts, Inc., Theraclion, Sonablate, Alpinion Medical Systems Co., Ltd., Shanghai Carnation Medical Technology Co., Ltd., Insightec, FUS Instruments Inc., Mianyang Sonic Electronic, Profound Medical, Merz Pharmaceuticals GmbH, Image Guided Therapy, and Promedica Bioelectronics s.r.l. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
*Definition: High-Intensity focused ultrasound (HIFU) is a medical procedure that uses ultrasound waves to treat conditions such as tumor. It is a non-invasive procedure and uses focused ultrasound waves to thermally ablate a portion of tissue, by destroying it with intense heat. The intense heat causes tissue coagulation, necrosis, cavitation, and heat shock in the cells, resulting in the destruction of the ablated tissue.
Share
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
